Cell Therapy: what are the top startups?
In our cell therapy market deck, you will find everything you need to understand the market
SUMMARY
Cell Therapy: what are the top startups? The strongest names today are Orca Bio, Kyverna, Cabaletta Bio, Cellares, Immatics, Iovance, Sana, Kelonia, Orna, and Dispatch Bio, because they show the clearest mix of regulatory maturity, clinical evidence, commercial proof, strategic validation, or infrastructure leverage.
The market is no longer a single “best startup” race. The strongest answer depends on whether we are looking at near-commercial products, autoimmune CAR-T, in vivo delivery, solid tumors, regenerative medicine, manufacturing, or pharma validation.
Orca Bio has the cleanest private near-commercial case because its 2026 financing was directly tied to potential commercialization. That matters more than a generic platform round because it signals launch preparation, not just scientific ambition.
Iovance changes the benchmark because it is already generating real product revenue. In a sector full of trial updates and platform claims, commercial revenue creates a harder yardstick for everyone else.
Autoimmune cell therapy looks like the hottest clinical category right now. Kyverna leads on filing maturity, Cabaletta leads on breadth of autoimmune evidence, and Cartesian matters because its mRNA CAR-T format could make the category more repeatable and outpatient-friendly.
In vivo cell therapy has moved from speculative to strategic. Lilly’s Kelonia and Orna deals, plus AbbVie’s Capstan acquisition, suggest pharma buyers now see injectable or in-body cell engineering as a serious path to scale.
Off-the-shelf cell therapy is credible again, but not equally credible everywhere. Orca and Allogene look more concrete than most, while Fate, Century, Wugen, and AvenCell still need more decisive human data or narrower clinical wins.
Solid tumors remain the hardest proving ground. Iovance has commercial proof, Immatics has the strongest next-wave clinical path, and Dispatch Bio is the freshest high-conviction moonshot because it attacks tumor targeting from a different angle.
Regenerative medicine is becoming more evidence-based. Sana’s diabetes data, BlueRock’s Parkinson’s Phase 3 benchmark, and Aspen’s human follow-up data make the category feel less like a distant stem-cell promise and more like a real clinical race.
Manufacturing may be one of the most important hidden categories. Cellares stands out because it combines capital, customer commitments, and patient-dose manufacturing, which is a stronger signal than automation language alone.
The most interesting emerging watchlist includes Oricell, Aspen Neuroscience, Azalea, GentiBio, AvenCell, Tr1X, and Ori Biotech. These names are not always the loudest, but each has a fresh signal that makes it worth tracking before the market fully prices it in.
The clean conclusion is that the top cell therapy map now has to include product companies, platform companies, pharma-validated in vivo assets, regenerative medicine players, and manufacturing infrastructure. Reputation alone is no longer enough.
This market map, featured in our cell therapy market deck, highlights top companies and startups in the cell therapy market
Which cell therapy startups are closest to real commercial scale today?
Clearly, if we ask who is closest to becoming a real product company, Orca currently has the cleanest private-company case.
Orca’s edge is timing. In January 2026, it raised $250 million specifically to prepare for potential Orca-T commercialization. That is more meaningful than a broad platform round because the money is tied to launch readiness. The FDA had already accepted Orca-T under Priority Review in October 2025, with a 2026 PDUFA timeline. Among private cell therapy companies, that combination is rare: late regulatory stage, serious launch capital, and a product built around a painful transplant bottleneck.
Iovance is already commercial, so it should be treated as the benchmark rather than the emerging pick. In Q1 2026, it reported $71.4 million in net product revenue, including $60.2 million from Amtagvi, and guided to $350 million to $370 million in 2026 product revenue. That gives us a real yardstick: Orca is the private near-approval story, while Iovance shows what “commercial cell therapy” looks like once the product is actually on the market.
Immatics sits between them. It is not commercial yet, but anzu-cel is on a Phase 3 path, with interim and final analyses expected to be triggered in 2026 and a first commercial launch planned in 2027. Compared with Orca, Immatics is less of a near-PDUFA story. Compared with most solid-tumor cell therapy startups, it is much more advanced. That is why it belongs high in this category.
So, Orca Bio is the clearest private leader here, with Iovance and Immatics as the best public-market comparables.
If you want more recent data on this point, please see our latest cell therapy market report.
Which in vivo cell therapy startups are being taken most seriously right now?
Kelonia is the strongest signal, Orna is the platform signal, and Capstan set the autoimmune benchmark.
Kelonia is the loudest 2026 proof.
Lilly agreed in April 2026 to acquire Kelonia for up to $7 billion, including $3.25 billion upfront. That is a huge price for a Phase 1-stage in vivo CAR-T company. The reason it matters is the comparison: Orna’s February 2026 Lilly deal was worth up to $2.4 billion, and AbbVie bought Capstan in 2025 for $2.1 billion. Kelonia was priced above both, which tells us Lilly was not just buying “another in vivo platform.” It was paying up for Kelonia’s lead position in lentiviral in vivo anti-BCMA CAR-T.
Orna is still important, but for a different reason.
Its value is less about one advanced clinical asset and more about engineered circular RNA plus LNP delivery. Lilly buying both Orna and Kelonia in the same year tells us something useful: in vivo cell therapy is not being treated as a cute experiment anymore. The strategic race is now about which delivery architecture can make CAR-T injectable, scalable, and repeatable.
Capstan is the autoimmune reference point.
AbbVie bought it to get a targeted LNP anti-CD19 in vivo CAR-T approach for B-cell-driven autoimmune diseases. Compared with Kelonia, Capstan was more autoimmune-focused and earlier in the public clinical story. Compared with Orna, it looked more directly tied to a specific CD19 autoimmune product logic. Together, these three deals make the category feel real.
Among still-watchable independent names, Azalea, Umoja, and Sana matter most.
Azalea is earlier, but its $82 million November 2025 launch financing came at exactly the right moment, after buyers had already validated the category. Umoja has longer-standing in vivo CAR-T work. Sana deserves a place here because its May 2026 preclinical data showed cell-specific delivery and deep B-cell depletion in non-human primates. Still, we should keep the hierarchy clear: Kelonia, Orna, and Capstan are the proof points; Azalea, Umoja, and Sana are the next names to monitor.
As this chart shows, and as featured in our cell therapy market deck, search interest in stem cell therapy has been rising steadily
Which autoimmune cell therapy startups look strongest today?
Kyverna leads on regulatory maturity, Cabaletta leads on breadth of autoimmune data, and Cartesian is the differentiated outsider.
This is currently one of the hottest cell therapy categories, and the ranking is no longer just a matter of who has the best story.
Kyverna is first because it has moved furthest toward approval. In May 2026, it initiated a rolling BLA submission for miv-cel in stiff person syndrome after FDA alignment. That is a more advanced signal than another small autoimmune CAR-T update. It means Kyverna has reached the part of the race where the debate becomes filing quality, launch prep, and regulatory execution.
Cabaletta is probably the more interesting portfolio story. In June 2026, it said 83% of dermatomyositis patients in its RESET-Myositis study would have met the registrational primary endpoint, with responses maintained off immunomodulators through follow-up as long as 1.5 years. It also named systemic sclerosis as a second pivotal indication and plans a roughly 25-patient registrational study in Q4 2026. Compared with Kyverna, Cabaletta is a bit behind on filing maturity. Compared with nearly everyone else in autoimmune CAR-T, it has broader proof across diseases.
Cartesian is the one we should not bury. Its Descartes-08 program has randomized Phase 2b data in generalized myasthenia gravis, published in Nature Medicine in 2026, with 26 randomized patients. The key difference is the format: mRNA CAR-T, repeat dosing, outpatient administration, and no lymphodepletion. If autoimmune cell therapy stays focused on rare, severe patients, Kyverna and Cabaletta look stronger. If the market expands toward safer repeatable treatment, Cartesian becomes much more interesting.
Allogene is a watchlist name rather than a leader in this category. Its April 2026 $200.4 million raise and ALLO-329 preclinical data keep it relevant, but it has not yet earned the same rank as Kyverna or Cabaletta in autoimmune human evidence. Today, we would put Allogene behind the top three, but not ignore it.
If you want more recent data on this point, please see our latest cell therapy market report.
Which off-the-shelf cell therapy startups are actually credible again?
Orca Bio and Allogene are the most credible near-term names, while Fate, Century, Wugen, and AvenCell are more conditional bets.
Orca is unusual because it is not a classic universal CAR-T company, but it is the most advanced allogeneic cell therapy story in this group. Orca-T is under FDA review, and that matters more than another platform slide about scalable manufacturing. If approved, Orca would force the market to take allogeneic precision-cell products more seriously again.
Allogene is still the purest public allogeneic CAR-T platform name. It has the manufacturing logic, gene-editing history, and fresh capital after its April 2026 financing. But compared with Orca, it has less near-term regulatory clarity. Compared with Cabaletta or Kyverna in autoimmune disease, it still needs stronger human proof for its autoimmune pivot.
Fate and Century are the iPSC-derived bets. Fate remains relevant because it is still presenting off-the-shelf CAR-T work in oncology and autoimmune disease, and it extended runway into 2028 after restructuring. Century is earlier after refocusing, but its iPSC-derived islet and CD19 immune-cell programs keep it in the conversation. The honest read is that both companies still need decisive clinical data. They are important, but not top-tier leaders today.
Wugen and AvenCell are narrower, but they have real movement. Wugen raised $115 million in 2025 to advance WU-CART-007 in a global pivotal trial for T-ALL/T-LBL. AvenCell dosed the first patient in April 2026 with AVC-203, a dual CD19/CD20 allogeneic CAR-T, and prepared EHA 2026 data for its switchable CD123 program. These are not broad market leaders yet, but they are much more concrete than the average off-the-shelf promise.
This chart, featured in our cell therapy market deck, shows annual VC investment in cell therapy startups
Which cell therapy startups are most credible in solid tumors?
Iovance is the commercial proof, Immatics is the late-stage pipeline leader, and Dispatch Bio is the freshest moonshot.
Solid tumors are where cell therapy has been overpromised for years, so we should reward hard evidence more than ambition.
Iovance wins on commercial proof. Amtagvi is already generating product revenue, and that puts Iovance in a different category from preclinical or early clinical solid-tumor startups. The limitation is also clear: TIL therapy is complex, individualized, and still has heavy operational demands. So Iovance proves that solid-tumor cell therapy can sell, but it does not solve every scaling problem.
Immatics is the cleaner next-wave leader. Its PRAME-targeted anzu-cel is heading through key 2026 analyses, with a planned first launch in 2027. Compared with Iovance, Immatics has less commercial proof. Compared with most engineered solid-tumor cell therapy startups, it has a much more advanced clinical path. The real advantage is that PRAME could support a repeatable franchise across several tumor types, rather than one isolated product.
Dispatch Bio is the startup that feels newly hot. It launched in July 2025 with $216 million, backed by ARCH, the Parker Institute, Bristol Myers Squibb, and major academic founders. Its idea is very different: use a tumor-specific viral vector to mark cancer cells with a synthetic antigen, then make engineered immune cells attack that marker. Today, Dispatch should rank behind Iovance and Immatics because it lacks comparable clinical proof. But as a fresh company, the launch size and syndicate are hard to ignore.
Oricell is the China-linked emerging name to watch. It raised $70 million in January 2026 and more than $110 million in April 2026 to accelerate global solid-tumor CAR-T development. That repeated financing is more useful than one isolated round because it suggests the company is preparing for a broader global push. ArsenalBio also remains relevant because it raised a $325 million Series C in 2024 for programmable T-cell therapies, though that signal is older than the fresher Dispatch and Oricell updates.
If you want more recent data on this point, please see our latest cell therapy market report.
Which cell therapy startups are making regenerative medicine feel real?
Sana is the strongest independent signal, BlueRock is the most advanced clinical benchmark, and Aspen is the emerging Parkinson’s name.
Sana has the most provocative recent proof. In March 2026, it reported 14-month follow-up from a first-in-human hypoimmune-modified islet transplantation study without immunosuppression. The cells were still surviving, evading immune detection, and producing insulin. That is a bigger deal than a short early readout because immune rejection is one of the core problems in diabetes cell therapy. Compared with Century’s iPSC-derived islet plan, Sana is further ahead in human proof.
BlueRock is the most advanced Parkinson’s cell therapy benchmark, but it is Bayer-owned, so we should not treat it like a venture-backed startup. In September 2025, it dosed the first patient in exPDite-2, a pivotal Phase 3 trial of bemdaneprocel, described as the first Phase 3 allogeneic pluripotent stem cell-derived therapy trial in Parkinson’s disease. If we rank purely by clinical maturity, BlueRock is ahead of Aspen.
Aspen is the independent emerging name. In March 2026, it reported positive 12-month data from its ASPIRO Phase 1/2a trial of sasineprocel, an autologous iPSC-derived therapy for Parkinson’s disease. Compared with BlueRock, Aspen is earlier and autologous. Compared with most regenerative medicine startups, it has human follow-up data, which already separates it from the crowd.
Century and bit.bio are adjacent watchlist names. Century is pushing an iPSC-derived islet program toward an IND, but it is still behind Sana in human validation. bit.bio is not a therapeutic-product leader today since it is more of an enabling company. Its January 2026 $50 million Series C matters because reliable human cell programming could become infrastructure for drug discovery and, later, cell therapy development.
This chart, featured in our cell therapy market deck, shows how Legend Biotech is winning in cell therapy
Which startups are fixing the cell therapy manufacturing bottleneck?
Cellares is the clear category leader; Ori Biotech is the credible challenger. In cell therapy, manufacturing is not boring infrastructure. It often decides whether a therapy can be delivered at all.
Cellares is ahead because it has three things at once: capital, customers, and clinical use. Its Series D reached $277 million in June 2026 after ARK Invest joined the round. It also has a 10-year commercial supply agreement with Cabaletta and a $380 million capacity reservation and supply agreement with Bristol Myers Squibb. Those customer signals matter because they show Cellares is not only selling automation to investors; therapy developers are reserving capacity.
The most important update is that Cellares has moved into patient dosing. In 2026, it delivered GMP cell therapy doses manufactured on the Cell Shuttle platform for Cabaletta’s rese-cel program. That is the line between “nice manufacturing robot” and actual clinical infrastructure.
Ori Biotech is behind Cellares, but it is not just background noise. In May 2026, Ori and ImmuXell announced that the first clinical patient had been dosed with a TCR-T therapy manufactured on Ori’s IRO platform. The comparison is straightforward: Cellares has larger funding, bigger customers, and broader capacity commitments; Ori has a fresh clinical-use proof point and could still become a strong platform if it converts more partners.
If you want more recent data on this point, please see our latest cell therapy market report.
Which cell therapy startups are getting the strongest fresh funding signals?
Orca, Cellares, Dispatch Bio, Allogene, Oricell, Wugen, Aspen, and Azalea are the names that stand out.
Funding tells us where investors are still willing to carry expensive technical risk.
The largest recent checks are going to three kinds of companies. First, near-commercial assets: Orca’s $250 million round was tied to potential launch readiness. Second, industrial infrastructure: Cellares’ expanded Series D shows investors still believe manufacturing is a chokepoint worth owning. Third, category-creation bets: Dispatch launched with $216 million for a new solid-tumor strategy, and Azalea launched with $82 million for in vivo cell engineering.
Allogene’s April 2026 financing is a different type of signal. It is not as clean as Orca’s launch-readiness round or Cellares’ infrastructure round because Allogene still needs stronger clinical proof in its new priorities. But the raise matters because public investors were still willing to fund allogeneic CAR-T after several years of skepticism around the category.
Oricell and Wugen show where specialized clinical investors still see upside. Oricell raised twice in 2026 for solid-tumor CAR-T expansion, while Wugen raised $115 million in 2025 around a pivotal allogeneic program. Aspen’s reported $155 million Series C also stands out because regenerative neurology is expensive, slow, and hard to finance without credible human data.
This chart, featured in our cell therapy market deck, shows annual funding in cell therapy startups
Which cell therapy startups have the strongest Big Pharma validation?
Kelonia, Orna, Capstan, EsoBiotec, Cellares, GentiBio, and Dispatch Bio have the clearest strategic validation. This category matters because pharma buyers are usually less impressed by broad platform language than startup decks suggest.
Kelonia is the strongest validation signal today. Its Lilly deal was larger than Orna’s and Capstan’s, and it came after both had already validated the in vivo category. That sequencing matters. Lilly had already bought Orna in February 2026, then came back two months later and paid even more for Kelonia. We can say pretty clearly that Lilly did not view these as interchangeable platforms.
Orna and Capstan still matter because they define the in vivo autoimmune side of the market. Orna brought circular RNA and LNP engineering. Capstan brought a targeted LNP anti-CD19 CAR-T approach for B-cell autoimmune disease. EsoBiotec adds another version of the same story: AstraZeneca bought an in vivo platform in March 2025 to make cell therapy faster and more accessible than ex vivo manufacturing.
Cellares has strategic validation without being acquired. The BMS capacity reservation and Cabaletta supply agreement tell us large and clinical-stage companies are willing to outsource part of the manufacturing future to Cellares. That is a different kind of trust than M&A, but it may be just as important.
GentiBio is a quieter name with a real 2026 signal. BMS formed a Treg therapy collaboration with GentiBio in June 2026, with up to $1.9 billion in milestones. Compared with autoimmune CAR-T, Treg therapy is less noisy right now. Still, BMS putting that kind of milestone structure around GentiBio tells us pharma has not abandoned immune-tolerance cell therapies.
If you want more recent data on this point, please see our latest cell therapy market report.
Which under-the-radar cell therapy startups should we watch now?
Azalea, GentiBio, Tr1X, AvenCell, Aspen, Oricell, and Dispatch Bio are the names that deserve a place on the radar.
Azalea is early, but the timing is excellent. It launched in November 2025 with $82 million to engineer cells inside patients using EDVs and transient CRISPR-Cas9 cargo. After the Kelonia, Orna, and Capstan deals, an independent in vivo engineering startup with fresh capital becomes more interesting than it would have looked two years ago.
GentiBio and Tr1X are the immune-tolerance names to watch. GentiBio dosed the first participant in its POLARIS Phase 1 trial of GNTI-122 in type 1 diabetes in March 2026, after FDA IND acceptance and Fast Track designation in 2025. Tr1X presented first clinical data for TRX103 in February 2026 and announced more ASGCT 2026 data. These are early signals, but they keep Treg and Tr1 therapy alive in a market currently dominated by CAR-T headlines.
AvenCell is a good example of a company that could be missed because it is not attached to the biggest trend words. It dosed the first patient in April 2026 with AVC-203, a dual CD19/CD20 allogeneic CAR-T, and prepared 2026 data for a switchable CD123 program in AML. Compared with Allogene, it is much less established. Compared with most tiny allogeneic players, it has fresher clinical movement.
Aspen, Oricell, and Dispatch have already appeared above, but each deserves to return here for a different reason. Aspen has human Parkinson’s follow-up data. Oricell has repeated 2026 financing around solid tumors. Dispatch has one of the most unusually large and credible recent launches in the sector. These three are not “unknown,” but they are still under-discussed relative to the evidence they now have.
This chart, featured in our cell therapy market deck, compares the main business model options for cell therapy biotech companies
Which famous cell therapy startups still deserve the hype?
Iovance, Immatics, Sana, Fate, Allogene, Lyell, and Century still matter, but the ranking is uneven.
The thing is, a famous cell therapy name is not automatically a current leader.
Iovance still deserves respect because it has real revenue. Immatics deserves it because it has a late-stage solid-tumor path. Sana deserves it because its hypoimmune data could open a much larger regenerative medicine story. Those three have the strongest “still relevant now” case among the better-known names.
Allogene, Fate, Lyell, and Century are more conditional. Allogene has fresh capital and platform history, but it needs stronger autoimmune human data. Fate still has iPSC-derived off-the-shelf relevance, but the market needs to see clearer clinical differentiation after restructuring. Lyell has serious infrastructure and ambition, though the next data need to prove that its engineered T-cell biology changes outcomes. Century has refocused around iPSC-derived islets and autoimmune programs, but it is still earlier than Sana or Immatics in proof.
So the clean takeaway is this: the famous names are not all fading, but they are no longer enough. Today’s best cell therapy map has to include near-approval private companies, newly validated in vivo platforms, autoimmune CAR-T specialists, regenerative medicine players, and manufacturing startups.
So, who are the top cell therapy startups right now?
The top cell therapy startups right now are Orca Bio, Kyverna, Cabaletta Bio, Cellares, Immatics, Iovance, Sana, Kelonia, Orna, and Dispatch Bio.
The most important emerging watchlist is Oricell, Aspen Neuroscience, Azalea, GentiBio, AvenCell, and Ori Biotech.
Orca Bio is the strongest private near-commercial leader. Kyverna and Cabaletta are the strongest autoimmune cell therapy names, with Kyverna ahead on regulatory maturity and Cabaletta ahead on breadth of disease evidence. Cellares is the clearest manufacturing winner because it has moved beyond promise into customer commitments and patient-dose manufacturing.
Immatics and Iovance are the strongest solid-tumor names, but for different reasons: Iovance has revenue, while Immatics has the more interesting next-wave engineered pipeline. Sana is the most strategically interesting regenerative medicine company because its diabetes data attack the immune-rejection problem directly. Kelonia and Orna have already been acquired, but their deal values are too important to leave out because they reset the in vivo cell therapy benchmark. Dispatch Bio is the freshest high-conviction solid-tumor moonshot.
The emerging list is probably the most interesting part. Oricell has fresh global solid-tumor financing momentum. Aspen has human Parkinson’s data. Azalea is an early in vivo engineering bet at the right time. GentiBio and Tr1X keep immune tolerance cell therapy in the race. AvenCell has recent allogeneic clinical movement. Ori Biotech is chasing Cellares from behind in manufacturing automation.
| Category | Startups selected and why |
|---|---|
| Near-commercial cell therapy | Orca Bio leads private companies because it combines FDA Priority Review and launch-readiness financing; Iovance is the commercial benchmark; Immatics is the strongest late-stage solid-tumor comparator |
| In vivo cell therapy | Kelonia leads on deal strength; Orna validates the circular RNA/LNP route; Capstan anchors autoimmune in vivo CAR-T; Azalea, Umoja, and Sana are the watchlist |
| Autoimmune cell therapy | Kyverna leads on regulatory maturity; Cabaletta leads on breadth of autoimmune data; Cartesian is the differentiated mRNA CAR-T outsider; Allogene is a lower-confidence but important watchlist name |
| Off-the-shelf cell therapy | Orca and Allogene are the most credible near-term names; Fate and Century keep the iPSC route alive; Wugen and AvenCell have narrower but real clinical movement |
| Solid-tumor cell therapy | Iovance has commercial proof; Immatics has the strongest next-wave clinical path; Dispatch is the freshest moonshot; Oricell and ArsenalBio are serious challengers |
| Regenerative cell therapy | Sana has the strongest independent diabetes signal; BlueRock is the Parkinson’s clinical benchmark; Aspen is the emerging independent Parkinson’s name; Century and bit.bio are adjacent watchlist companies |
| Cell therapy manufacturing | Cellares is clearly ahead because of funding, customer commitments, and patient-dose manufacturing; Ori Biotech is the credible challenger with a fresh clinical-use milestone |
| Fresh funding | Orca, Cellares, Dispatch, Allogene, Oricell, Wugen, Aspen, and Azalea stand out because investors are funding either launch readiness, infrastructure, or category-creation risk |
| Big Pharma validation | Kelonia, Orna, Capstan, EsoBiotec, Cellares, GentiBio, and Dispatch show the strongest external validation through M&A, partnerships, customer commitments, or strategic investors |
| Emerging watchlist | Azalea, GentiBio, Tr1X, AvenCell, Aspen, Oricell, Dispatch, and Ori Biotech are the names that look most worth tracking before they become obvious |
This chart, featured in our cell therapy market deck, shows how market revenue is split across customer segments in the cell therapy market
OUR METHODOLOGY
The main question behind this analysis is difficult to answer cleanly because “top cell therapy startup” can mean very different things depending on the angle. A company may look strongest on commercial scale, regulatory maturity, clinical data, manufacturing infrastructure, in vivo delivery, regenerative medicine, or Big Pharma validation.
So we did not treat the market as one intuition-led ranking. We broke the question into the dimensions that seemed most useful for understanding where the sector is actually moving now: near-commercial products, in vivo cell therapy, autoimmune disease, off-the-shelf approaches, solid tumors, regenerative medicine, manufacturing, fresh funding, pharma validation, and emerging watchlist names.
Within each dimension, we prioritized recent signals over reputation. We looked at 2025–2026 regulatory updates, clinical progress, revenue, financing rounds, acquisitions, strategic partnerships, customer commitments, and manufacturing milestones. The goal was to separate companies with current evidence from companies still mostly carried by older platform narratives.
We also weighted signals differently depending on the category. Revenue and launch readiness mattered most for commercial scale. Human data and regulatory progress mattered most in autoimmune and regenerative medicine. Acquisition value and buyer behavior were especially useful in in vivo cell therapy, where many programs are still early. In manufacturing, customer commitments and patient-dose production mattered more than automation claims alone.
That is why the final answer is not a simple popularity list. It is a structured aggregation of recent signals across the parts of the market that matter most. The companies that appear strongest are the ones where several pieces of evidence now point in the same direction.
Key sources used for this analysis include: Orca Bio on FDA Priority Review for Orca-T, Business Wire on Orca Bio’s $250 million commercialization financing, Iovance Q1 2026 results and FY2026 guidance, Lilly on the Kelonia acquisition, Lilly on the Orna acquisition, AbbVie on the Capstan acquisition, AstraZeneca on the EsoBiotec acquisition, BioSpace on Kyverna’s rolling BLA submission, Cabaletta Bio on RESET-Myositis and autoimmune development, Nature Medicine on Cartesian’s Descartes-08 Phase 2b data, and ClinicalTrials.gov on the Descartes-08 study record.
Additional key sources include: Cellares on its $277 million Series D and clinical manufacturing update, BlueRock on its Phase 3 bemdaneprocel Parkinson’s trial, BioSpace on Sana’s 14-month hypoimmune islet transplantation data, Aspen Neuroscience on 12-month ASPIRO data, Dispatch Bio on its $216 million launch, Oricell on its $110 million pre-IPO financing, Wugen on its $115 million financing and pivotal WU-CART-007 trial, AvenCell on first patient dosing with AVC-203, BioSpace on Azalea Therapeutics’ $82 million launch, Allogene’s investor news page, and PharmaPhorum on the BMS and GentiBio Treg collaboration.
This chart, featured in our cell therapy market deck, shows how CAR-T cell therapy technology has evolved over time
Related blog posts
- How strong is fundraising in the cell therapy market right now?
- Which companies have raised the most funding in the cell therapy market?
- Which companies are the most valued in the cell therapy market?
- How's Legend Biotech doing these days?
